Musa Özgür ÖZYİĞİT, Fikriye Ecem KURUOĞLU, Deniz NAK, Zehra AVCI KÜPELİ, Zeynep Merve EKİCİ, Davut KOCA, Talha AVCILAR, Mustafa Eren ŞAHİN, Yavuz NAK, Abid Hussain SHAHZAD

Lokal İleri Köpek Meme Tümörlerinde Neoadjuvan Tedavide Doksorubisin ve Siklofosfamidin Etkinliği ve Toksisitesi

Bu çalışmanın amacı, lokal ileri meme tümörlü köpeklerde neoadjuvan kullanımda doksorubisin ve siklofosfamidin etkinliğini ve toksisitesini araştırmaktır.Bu çalışmada lokal ileri meme tümörlü 8-14 yaş aralığında 16 köpek kullanılmıştır. Neoadjuvant kemoterapi öncesinde tüm köpeklerden Tru-Cut biyopsisi ve ilgili lenf nodundan ince iğne aspirasyon biyopsisi ile örnekler alınmıştır. Numuneler histopatolojik inceleme için patoloji laboratuvarına gönderilmiştir. Histopatoloji sonuçlarına göre, meme tümörlerine adenokarsinom (n=13), tubulopapiller karsinom (n=2) ve malign miks tümör (n=1) tanısı konmuştur. Neoadjuvan kemoterapi olarak, 3 haftalık aralıklarla 4 kez yavaş IV enjeksiyon ile doksorubisin (25-30 mg/m2) ve siklofosfamid (100 mg/m2) uygulanmıştır. Yan etki olarak; kusma, anoreksi, uyuşukluk, kilo kaybı, alopesi, enterit, hematüri ve deri ülseri gibi klinik bulgular, nötropeni ve hematokrit değerlerinde azalma gibi laboratuvar bulguları gözlenmiştir. Kemoterapiden önce ve tedavinin bitiminde 4 hafta sonra tümörlerin en uzun çapına dayanarak, 2 köpekte (%12.5) tam cevap, 9 köpekte (%56.25) kısmi cevap ve 5 köpekte (%31.25) stabil hastalık belirlenmiştir. Sonuç olarak, lokal ileri meme tümörlü köpeklerde neoadjuvan kemoterapi için doksorubisin ve siklofosfamid kombinasyonunun toksisitesi ve etkinliği kabul edilebilir ve tedavide umut verici olduğu görülmüştür.

Efficacy and Toxicity of Doxorubicin and Cyclophosphamide for the Neoadjuvant Treatment of Locally Advanced Stage Canine Mammary Tumors

The aim of this study was to investigate the effect and toxicity of a doxorubicin cyclophosphamide combination for neoadjuvant use in dogs with locally advanced mammary tumors. A total of 16 dogs with locally advanced mammary tumors aged 8-14 years was used in this study. Samples were taken from all the dogs via Tru-Cut biopsy and fine needle aspiration biopsy of the lymph nodes prior to neoadjuvant chemotherapy. The samples were sent to the pathology laboratory for histopathological examination. Based on the histopathology results, mammary tumors were diagnosed as adenocarcinoma (n=13), tubulopapillary carcinoma (n=2) and malignant mixed tumors (n=1). For the neoadjuvant chemotherapy, doxorubicin (25-30 mg/m2) and cyclophosphamide (100 mg/m2) were administered via slow IV injection 4 times at 3-week intervals. Clinical findings such as fever, vomiting, anorexia, lethargy, weight loss, alopecia, enteritis, hematuria, and skin ulceration and laboratory findings such as a decrease in neutropenia and hematocrit values were observed. Based on the longest diameter of the tumors before and after four weeks of chemotherapy, a complete response was detected in 2 dogs (12.5%), a partial response was observed in 9 dogs (56.25%) and the disease was stable in 5 dogs (31.25%). According to results, the toxicity, and efficacy of a doxorubicin and cyclophosphamide combination for neoadjuvant chemotherapy in dogs with locally advanced mammary tumors is acceptable, and the treatment is promising.

PDF

___

1. Sleeckx N, Rooster HD, Veldhuis Kroeze EJB, Ginneken CV, Brantegem LV: Canine mammary tumours, an overview. Reprod Domest Anim, 46, 1112-1131, 2011. DOI: 10.1111/j.1439-0531.2011.01816.x
2. Von Euler H: Tumors of the mammary glands. In, Dobson JM, Lascelles BDX (Eds): BSAVA Manual of Canine and Feline Oncology. 3rd ed., 237-247, Glouscester, UK: BSAVA, 2011. DOI: 10.22233/9781905319749.16
3. Kivrak MB, Aydin I: Treatment and prognosis of mammary tumors in bitches. Inter J Vet Sci, 6 (4): 178-186, 2017.
4. Sorenmo KU, Kristiansen VM, Cofone MA, Shofer FS, Breen AM, Langeland M, Mongil CM, Grondahl AM, Teige J, Goldschmidt MH: Canine mammary gland tumours: A histological continuum from benign to malignant: Clinical and histopathological evidence. Vet Comp Oncol, 7, 162-172, 2009. DOI: 10.1111/j.1476-5829.2009.00184.x
5. Goldschmidt MH, Pena L, Zappuli V: Tumors of Mammary Gland. In, Meuten DJ (Ed): Tumors in Domestic Animals. 5th ed., 723-725, Willey Backwell, USA, 2017. DOI: 10.1002/9781119181200
6. Gustafson DL, Page RL: Cancer chemotheraphy. In, Withrow SJ, Vail DM, Page RL (Eds): Withrow & MacEwen’s Small Anımal Clinical Oncology. 5th ed., 157-179, Saint Louis, USA, Elsevier Saunders, 2013.
7. Biller B, Berg J, Garrett L, Ruslander D, Wearing R, Abbott B, Patel M, Smith D, Bryan C: 2016 AAHA oncology guidelines for dogs and cats. J Am Anim Hosp Assoc, 52 (4): 181-204, 2016. DOI: 10.5326/JAAHAMS-6570
8. Karayannopoulo M, Lafioniatis S: Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date. Rev Méd Vét, 167 (7-8): 192-200, 2016.
9. Specht J, Gralow JR: Neoadjuvant chemotherapy for locally advanced breast cancer. Semin Radiat Oncol, 19 (4): 222-228, 2009. DOI: 10.1016/j. semradonc.2009.05.001
10. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 26 (5): 778- 785, 2008. DOI: 10.1200/JCO.2007.15.0235
11. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Marrgolese R, Theoret H, Soran A, Wickerham DL, Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doksorubisin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 21 (22): 4165-4174, 2003. DOI: 10.1200/JCO.2003.12.005
12. Goldschmidt M, Pena L, Rasotto R, Zappulli V: Classification and grading of canine mammary tumors. Vet Pathol, 48 (1): 117-131, 2011. DOI: 10.1177/0300985810393258
13. Nguyen SM, Thamm DH, Vail DM, London CA: Response evaluation criteria for solid tumours in dogs (v1.0): A Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol, 13 (3): 176-183, 2015. DOI: 10.1111/vco.12032
14. Veterinary Co-operative Oncology Group: Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol, 14 (4): 417-446, 2016. DOI: 10.1111/vco.283
15. Miles D, Von Minckwitz G, Seidman AD: Combination versus sequential single-agent theraphy in metastatic breast cancer. Oncologist, 7 (Suppl.-6): 13-19, 2002. DOI: 10.1634/theoncologist.2002-0013
16. Perez EA: Paclitaxel in breast cancer. Oncologist, 3, 373-389, 1998.
17. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N: Paclitaxel after doksorubisin plus cyclophosphamide as adjuvant chemotheraphy for node- positive breast cancer: Result from NSABP B-28. J Clin Oncol, 23 (16): 3686-3696, 2005. DOI: 10.1200/JCO.2005.10.517
18. De M Souza CH, Toledo-Piza E, Amorin R, Barboza A, Tobias KM: Inflammatory mammary carcinoma in 12 dogs: Clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J, 50, 506-510, 2009.
19. Todorova I, Simeonova G, Simeonov R, Dinev D: Efficacy and toxocity of doksorubisin and cyclophosphamide chemoterapy in dogs with spontaneous mammary tumours. Trakia J Sci, 3 (5): 51-58, 2005.
20. Goorts B, Van Nijnatten TJA, De Munck L, Moossdorff M, Heuts EM, De Boer M, Lobbes MBI, Smidt ML: Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat, 163, 83-91, 2017.
21. Lin Q, Lıu Y, Chen H, Lıu Y, Tang Q, Lıu J, Chen H: Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer. Mol Clin Oncol, 1 (5): 839-844, 2013. DOI: 10.3892/mco.2013.138